Survey on the Use of Medicines in Patients with Co-existing Hypertension and Type 2 Diabetes at the Internal Medicine Department of E Hospital in 2020-2022

Abstract

The study aims to describe the situation of using antihypertensive and hypoglycemic drugs, and the initial evaluation of the effectiveness of medications used in treating patients with concomitant hypertension and type 2 diabetes. Methods: A cross-sectional, retrospective study was performed on 179 medical records of patients with hypertension and type 2 diabetes, who were examined and treated at the Internal Medicine Department - E Hospital from April 2020 to December 2022. Information collected from medical records was processed using SPSS 26.0 statistical software. Result: Metformin (74.9%) and insulin (69.3%) were the main groups of hypoglycemic drugs. The rate of using a multi-drug regimen for diabetes (64.8%) was higher than that of monotherapy, in which the two-drug regimen of insulin and biguanide (metformin) was common (32.4%). The main groups of antihypertensive drugs used were ACE inhibitors and Ca channel blockers (72.6% and 57.5%, respectively). 60.3% of patients were treated according to a multi-drug regimen in which combination regimens of 2 groups of Ca channel blockers and ACE inhibitors were common (26.3%). There were no clinically significant interactions between antidiabetic and antihypertensive drugs. The rate of patients who reached the target blood pressure was 83.8%. The rate of patients achieving target blood glucose levels when discharged from the hospital was 40.9%. Conclusion: A multi-drug regimen was used more than monotherapy in the treatment of hypertension and diabetes. Most patients reached target blood pressure on discharge, however the number of patients achieving target blood glucose was quite limited. No drug interactions were found between drugs used to lower blood pressure and hypoglycemic drugs.